Interpace Biosciences, Inc. (IDXG) has seen some recent activity in the marketplace and its shares closed at $4.7900 yesterday. Investors are starting to take interest of IDXG as the  shares traded as high as $6.2000 and as low as $4.5200 in the prior market day.

Interpace Biosciences, Inc. (IDXG) average trading volume is 64.96K. However, in the prior market day Interpace Biosciences, Inc. (IDXG) exchanged 799,674 shares. The first support level on IDXG is $4.50 and the first resistance level on IDXG is $10.55. IDXG 50day moving average is $5.2460 and IDXG 200day moving average is $6.3413.

Interpace Biosciences, Inc. (IDXG) current performance has been shown by the recent movement in IDXG common shares. IDXG has performed -0.42% over the past 30 days, IDXG has performed -42.43% over the past 3 months and IDXG has shown -32.51% over the past 12 months. Interpace Biosciences, Inc. (IDXG) has a 12 month range of $3.8000 to $11.0000. Interpace Biosciences, Inc. (IDXG) is trading 25.72% from its 12 month low and -56.45% from its 12 month high. Interpace Biosciences, Inc. (IDXG) is indicating a 3.39% short float indicating the quantity short in the float.

IDXG has 3.98M shares outstanding and 3.98M shares in the float. Interpace Biosciences, Inc. (IDXG) presently has a market cap of $19.06M and income of $-27.90M. The EPS next quarter for IDXG is -1.22 and projected EPS net year is 75.10%. The market cap of Interpace Biosciences, Inc. (IDXG) at $19.06M represents how many Investors own shares of IDXG and is calculated off the last price ($4.7900) of IDXG and the quantity of shares outstanding (3.98M) with Interpace Biosciences, Inc. (IDXG).

Interpace Biosciences, Inc. (IDXG) has aggregate cash (mrq) of 2.32M, aggregate cash per share (mrq) of 0.57, aggregate debt of IDXG is at 7.22M and aggregate debt/equity (mrq) is 18.43. Interpace Biosciences, Inc. (IDXG) operational cash flow (ttm) is -18.96M and IDXG leveraged free cash flow (ttm) is -4.74M.

IDXG is trading -11.39% below (bearish) its SMA20, -14.45% below (bearish) its SMA50 and -29.85% below (bearish) its SMA200.

Recent News:

In recent news, on April 27, 2020, it was announced, Interpace Biosciences Announces Contract with Lab Benefits Management Firm. In this news it stated, In-Network Access for More Than 3 Million Members Interpace Biosciences (IDXG) announced today that its subsidiary, Interpace Diagnostics, has entered into a contract with Avalon Healthcare Solutions (Avalon), a specialty benefit management company with more than 3 million members, focused on laboratory testing. The new contract, whose terms were not disclosed, includes two of the Southeastern U.S.’s largest Blue Cross Blue Shield plans where members can now take advantage of the benefits of ThyGeNEXT® and ThyraMIR® thyroid testing while reducing their out of pocket expenses due to Interpace’s status as an in-network provider. Interpace has successfully achieved positive medical coverage for its services through Medicare as well as other leading national and regional health plans and is now focused on establishing more contracts to optimize the adjudication process.

About Interpace Biosciences, Inc. (IDXG):

Interpace Diagnostics Group, Inc. provides molecular diagnostic tests. The company’s test consists of ThyGenX Thyroid Oncogene Panel (R), Thyroid miRNA(TM) and PancraGen(TM).